Exact Sciences Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Exact Sciences Corp 公司

Exact Sciences Corporation 是一家全球先进的癌症诊断公司。该公司提供一系列用于早期癌症检测和治疗指导的产品。其产品和服务专注于筛查和精准肿瘤学测试。该公司的研发工作主要集中在三个主要领域：结直肠癌筛查、MCED 测试开发和 MRD 测试开发。该公司的产品和服务包括 Cologuard 测试、Oncotype DX 乳腺复发评分测试、Oncotype DX 乳腺 DCIS 评分测试、Oncotype DX 结肠复发评分测试和 OncoExTra 测试。该公司的旗舰筛查产品 Cologuard 测试是一种非侵入性、基于粪便的脱氧核糖核酸 (sDNA) 筛查测试，它利用多目标方法检测与结直肠癌和癌前病变相关的 DNA 和血红蛋白生物标志物。Oncotype DX 乳腺复发评分测试检查患者乳腺肿瘤组织中 21 个基因的活性。

公司简介

公司代码EXAS

公司名称Exact Sciences Corp

上市日期Jan 30, 2001

成立日期1995

CEOMr. Kevin T. Conroy

员工数量6900

证券类型Ordinary Share

年结日Jan 30

公司地址5505 Endeavor Lane

城市MADISON

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编53719

电话16082845700

网址https://www.exactsciences.com/

公司代码EXAS

上市日期Jan 30, 2001

成立日期1995

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

Mr. Aaron Bloomer

Chief Financial Officer

13.62K

--

Ms. Kimberly J. (Kim) Popovits

Director

6.39K

--

Mr. James E. Doyle

Lead Independent Director

--

Ms. Kathleen Sebelius

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

收入明细

单位: USD更新时间: 4月6日周日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

地区USD

名称

营收

占比

United States (Country)

2.57B

93.15%

Outside of united states

189.09M

6.85%

业务

地区

业务USD

名称

营收

占比

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

股东统计

更新时间: 4月26日周六

持股股东

股东类型

持股股东

股东统计

占比

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

持股股东

股东统计

占比

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

股东类型

股东统计

占比

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

36.05%

Hedge Fund

6.23%

Research Firm

2.45%

Bank and Trust

1.53%

Pension Fund

1.22%

Individual Investor

1.08%

Sovereign Wealth Fund

0.50%

Private Equity

0.37%

机构持股

更新时间: 1月20日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q1

1377

200.62M

108.03%

+569.91K

2024Q4

1411

200.72M

108.09%

-225.66K

2024Q3

1375

190.82M

103.28%

-5.17M

2024Q2

1358

185.25M

100.40%

+6.59M

2024Q1

1347

168.41M

92.78%

-6.10M

2023Q4

1356

165.31M

91.41%

-11.01M

2023Q3

1337

167.70M

92.83%

-6.22M

2023Q2

1354

166.38M

92.24%

-10.65M

2023Q1

1343

167.01M

92.90%

-8.56M

2022Q4

1337

163.71M

92.15%

-9.28M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

18.85M

10.15%

-712.35K

-3.64%

Dec 31, 2024

Capital World Investors

17.54M

9.44%

+1.70M

+10.71%

Dec 31, 2024

The Vanguard Group, Inc.

16.95M

9.12%

-741.47K

-4.19%

Dec 31, 2024

Wellington Management Company, LLP

12.06M

6.49%

-2.27M

-15.86%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

7.66M

4.13%

+245.10K

+3.30%

Dec 31, 2024

State Street Global Advisors (US)

6.23M

3.36%

-447.40K

-6.70%

Dec 31, 2024

T. Rowe Price Associates, Inc.

5.62M

3.03%

+2.48M

+78.79%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.27M

2.3%

+876.99K

+25.85%

Dec 31, 2024

William Blair Investment Management, LLC

3.44M

1.85%

-840.44K

-19.61%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.12M

1.68%

+16.83K

+0.54%

Dec 31, 2024

持股ETF

更新时间: 4月6日周日

机构名称

占比

First Trust Nasdaq Lux Digi Health Solutions ETF

2.94%

First Trust NYSE Arca Biotechnology Index Fund

2.61%

Invesco Biotechnology & Genome ETF

2.34%

SPDR S&P Biotech ETF

2.09%

Nuveen ESG Mid-Cap Growth ETF

1.77%

Franklin Genomic Advancements ETF

1.42%

iShares Health Innovation Active ETF

1.39%

Direxion Daily S&P Biotech Bull 3X Shares

1.33%

ROBO Global Healthcare Technology & Innovation ETF

1.28%

VanEck Biotech ETF

1.17%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比2.94%

First Trust NYSE Arca Biotechnology Index Fund

占比2.61%

Invesco Biotechnology & Genome ETF

占比2.34%

SPDR S&P Biotech ETF

占比2.09%

Nuveen ESG Mid-Cap Growth ETF

占比1.77%

Franklin Genomic Advancements ETF

占比1.42%

iShares Health Innovation Active ETF

占比1.39%

Direxion Daily S&P Biotech Bull 3X Shares

占比1.33%

ROBO Global Healthcare Technology & Innovation ETF

占比1.28%

VanEck Biotech ETF

占比1.17%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Exact Sciences Corp

45.460USD

Exact Sciences Corp

45.460

概览

公司